Insuficiencia Cardiaca
Pulmonary arterial hypertension in adult congenital heart disease
Impact and Outcome
Data from GUTI-GUCH Registry
Claudio Gabriel Morós, Marisa Pacheco Otero, Gianina Faliva, María del Carmen Rubio, Mariana López Daneri, Isabel Torres, Inés Abella, Álvaro Sosa Liprandi, Liliana Noemí Nicolosi, María Grippo
Introduction
Adult Congenital Heart Disease (ACHD) is one of the fastest-growing cardiology subgroups in recent years within cardiology due to early detection as well as advancements in surgical and endovascular treatments. It is estimated that 85-90% of patients with congenital heart disease live to adulthood. The survival of these individuals creates complications and sequels that result in a higher rate of hospitalization and surgery, among other procedures.
It is estimated that 5% to 10% of patients with ACHD develop pulmonary hypertension (PH) as ACHD evolves, which is currently the most frequent cause of pulmonary arterial hypertension (PAH) after connective tissue diseases. Its appearance is related to worst prognosis in patients.
The objective of the presented research was to analyze the epidemiological and clinical characteristics, as well as pharmaceutical treatment of patients with PAH and its impact on survival.